<DOC>
	<DOCNO>NCT00784368</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( drug absorb body , distribute within body , remove body time ) itraconazole ( ITCZ ) oral solution participant Systemic Fungal Infection ( SFI ) febrile ( fever ) neutropenia ( FN , decrease white blood cell ) suspect fungal infection .</brief_summary>
	<brief_title>A Pharmacokinetic Study JK1211 ( Itraconazole Itrizole ) Oral Solution Participants With Deep Mycosis Those With Febrile Neutropenia Suspected Fungal Infection</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multicenter ( conduct 1 center ) uncontrolled ( competitive drug involve ) study . Participants SFI receive treatment ITCZ oral solution switch treatment intravenous ( vein ) infusion itraconazole ( ITCZ-intravenous ) ITCZ oral solution per Investigator 's discretion . All participant FN suspect fungal infection receive switch treatment ITCZ- intravenous ITCZ oral solution . The study include 3 period : Pre-observation period ( 7 day ) , Treatment period ( 85 day ITCZ oral solution monotherapy 99 day switch treatment ) Follow-up observation period ( 30 day ) . The participant receive ITCZ oral solution monotherapy receive ITCZ oral solution without ITCZ-intravenous dose range 20 milliliter ( ml ) per day 40 ml per day 12 week ( 85 day ) switch treatment receive 400 milligram ( mg ) per day ITCZ-intravenous twice first 2 day follow 200 mg per day ITCZ-intravenous 14 day administer treatment per ITCZ oral solution monotherapy . Efficacy primarily evaluate assess pharmacokinetics . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Cryptococcosis</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<mesh_term>Blastomycosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>In case participant deepseated mycosis ( systemic fungal infection [ SFI ] ) either clinically suspected case proven case All participant administer need hospitalize itraconazole intravenous treatment For participant febrile ( fever ) neutropenia ( decrease white blood cell ) suspect fungal infection persistent fever ( great equal 37.5 degree celsius ; great equal 3 day ) neutrophil count le 500 per cubic millimeter ( less 1000 per cubic millimeter expect decrease toward less 500 per cubic millimeter No past history hypersensitivity azole antifungal agent No current medication antifungal agent amphotericin B ( intravenous injection [ injection substance vein ] , tablet , syrup ) , nystatin ( tablet ) , fluconazole ( capsule , intravenous injection ) , flucytosine ( oral agent ) , miconazole ( intravenous injection , gel ) , micafungin ( intravenous infusion ) , fosfluconazole ( intravenous injection , ) voriconazole ( intravenous injection , tablet ) , liposomal amphotericin B ( intravenous injection ) , posaconazole No medication itraconazole formulation within last 28 day Participants history severe hepatic disease ( except hepatic dysfunction fungal infection ) congestive heart failure Female participant either pregnant , nursing , suspect pregnant become pregnant trial duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Mycoses</keyword>
	<keyword>Candidiasis</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>Cryptococcosis</keyword>
	<keyword>Blastomycosis</keyword>
	<keyword>Histoplasmosis</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>JK1211</keyword>
</DOC>